XZXiangzhong Zhao

Xiangzhong Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiangzhong Zhao has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Leping Shao

    Department of Nephrology (Fujian Provincial Clinical Research Center for Glomerular Nephritis), The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, China

    6 shared publications
  • Ruixiao Zhang

    Department of Nephrology Qingdao 266071, China

    3 shared publications
  • Yanhua Lang

    Department of Nephrology the Affiliated Qingdao Municipal Hospital of Qingdao University Qingdao China

    3 shared publications
  • Zhiying Liu

    Medical Research Center Qingdao 266555, China

    3 shared publications
  • Qian Zhang

    The Affiliated Hospital of Qingdao University and Institute of Genetics and Integrative Biology (Qingdao Branch of SJTU Bio-X Institutes), Qingdao University , Qingdao, 266003

    2 shared publications
  • Qing Xin

    Medical Research Center Qingdao 266555, China

    2 shared publications

Latest Publications

  • Open Access

    Targeted modification of cis-elements in the CUL3 gene to restore exon 9 inclusion for treating Gordon syndrome

    by Xiaomeng Shi, Shanshan Lu, Qian Tang, Xiangzhong Zhao

    The weak splice acceptor site (AS) of exon 9 underlies almost all pathogenic variants of Cullin3 (CUL3) causing exon 9 skipping in Gordon syndrome, emphasizing the need for splicing-targeted therapeutic strategies. This study explored universal therapeutic targets to modulate AS and investigated their potential and mechanisms for restoring normal splicing. Through bioinformatic prediction, minigene assays, EMSA, CRISPR/Cas9-mediated construction of mutant cell lines and RIP, three rescue sites in the polypyrimidine (Py) tract of intron 8 were identified, including A(-9)T, A(-10)T and AA(-9, -10)TT, with AA(-9, -10)TT most effectively promoting exon inclusion by extending the Py-tract to increase U2AF2 binding. Additionally, previous candidate target A18G was confirmed to rescue exon 9 skipping by weakening hnRNP A1 splicing inhibition in endogenous cell models. Our findings highlight the therapeutic potential of AA(-9, -10)TT and A18G in CUL3-related Gordon syndrome, suggesting the targeted modification of cis-elements could be an ideal and universal strategy to develop treatments for splicing-related diseases.


  • Detection of pleiotropic genetic factors and critical brain cell types linking insomnia with psychiatric disorders

    by Baiqiang Xue, Mingming Niu, Yuanchao Sun, Lin Wang, Chuanhong Wu, Yonghe Ding, Baokun Wang, Lixia Peng, Xiangyu Li, Haiyan Song, et al.

    Study Objectives: Insomnia and psychiatric disorders are frequently comorbid and heritable, yet their shared genetic architecture and neurobiological mechanisms remain poorly understood. We investigated the genetic overlap, biological pathways, and brain cell types linking insomnia with 12 psychiatric disorders. Methods: We analyzed genome-wide association study data from insomnia (Neff = 314,149) and 12 psychiatric disorders (Neff = 12,783–449,855). Genetic architecture was assessed using bivariate MiXeR. Shared loci were identified through conjunctional false discovery rate (conjFDR) and Association analysis based on SubSETs (ASSET). Gene-set enrichment was performed with MAGMA, and cell-type specificity was determined using SEISMIC analysis of single-cell RNA sequencing data from 36 brain cell types. Results: Significant genetic correlations emerged between insomnia and seven psychiatric disorders: attention-deficit/hyperactivity disorder (ADHD), anorexia nervosa (AN), anxiety disorders (ANX), autism spectrum disorder (ASD), bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCZ). Cross-trait analyses identified 70 shared genomic loci containing 97 candidate single nucleotide polymorphisms (SNPs), including novel associations: 7 with ADHD, 6 with AN, 3 with ANX, 3 with ASD, 5 with BD, 15 with MDD, and 19 with SCZ. Pathway enrichment analysis revealed GABAergic synapse signaling as a central mechanism. Cell-type analysis implicated eight cortical neuron subtypes—four GABAergic interneurons and four glutamatergic neurons. Of 71 genes mapped to shared loci, 33 showed significant expression in these neuronal populations. Conclusions: Our findings reveal extensive shared genetic architecture between insomnia and psychiatric disorders, converging on cortical GABA-glutamate circuitry dysfunction. These results identify potential therapeutic targets for comorbid conditions and demonstrate how integrating genetic epidemiology with cellular neuroscience can elucidate transdiagnostic mechanisms underlying neuropsychiatric comorbidity, informing precision medicine approaches.


  • Double synonymous mutations in exon 9 of the Cullin3 gene restore exon inclusion by abolishing hnRNPs inhibition

    by Zhiying Liu, Aihua Sui, Sai Wang, Li Cui, Qing Xin, Ruixiao Zhang, Yue Han, Leping Shao, Xiangzhong Zhao

    All mutations in exon 9 of the Cullin3 gene associated with pseudohypoaldosteronism type II (PHA II) contribute to exon skipping to different degrees, but the specific molecular mechanism of this aberrant splicing is still unclear. The aims of this study were to investigate the regulatory mechanism underlying two synonymous splicing events, c.1221A > G (p. Glu407Glu) and c.1236G > A (p. Leu412Leu), and to discover a therapeutic strategy for correcting this aberrant splicing by targeting potential regulatory sites. Through a series of RNA pulldown, silver staining, western blotting, small interfering RNA knockdown, in vitro overexpression and single or double site-directed mutagenesis experiments, we first explored the pathogenesis of exon 9 skipping caused by mutations in the CUL3 gene and verified that the main splicing regulators associated with the synonymous c.1221A > G and c.1236G > A mutations were heterogeneous nuclear ribonucleoproteins. In addition, we verified that introducing another synonymous mutation, c.1224A > G (A18G), significantly rescued the abnormal splicing caused by c.1221A > G and c.1236G > A, highlighting the therapeutic potential for the treatment of PHA II.


  • Novel gain‐of‐function mutation ofTRPC6Q134Pcontributes to late onset focal segmental glomerulosclerosis in a Chinese pedigree

    by Zhiying Liu, Haiyan Zhang, Shipeng Zhao, Qian Zhang, Ruixiao Zhang, Yue Han, Leping Shao, Xiangzhong Zhao

    Background: Focal segmental glomerulosclerosis (FSGS, OMIM®#603 965) is an overriding cause that leads to end‐stage renal disease (ESRD). As a member of TRP superfamily, mutations ofTRPC6gene are closely linked to FSGS. By now, 20 missense mutations have been reported, among them, nine gain‐of‐function (GOF), and five loss‐of‐function (LOF) mutations have been recognized according to the effect on TRPC6 channel activity. Systematic investigations of functional mutations will provide valuable evidences for understanding the pathophysiology of TRPC6 involved in FSGS. The aim of this study is to investigate the pathogenicity of a novel TRPC6 mutation p.Q134P in FSGS.Methods: High‐throughput sequencing was performed to analyse 436 genes which are associated with hereditary kidney diseases in a Chinese pedigree. Then we constructed TRPC6 expression plasmids of wide type and variant. Immunofluorescence, cell‐surface biotinylation assays and electrophysiology were used to analyse the localization, cell surface expression, and calcium transport activity of TRPC6.Results: A novel variant c.401A>C (p.Q134P) in exon 2 ofTRPC6gene was found. There was no significant difference between the expression levels of p.Q134P mutant and WT TRPC6 protein in the whole cell lysate and cell‐surface fraction. Q134P mutant‐bearing TRPC6 elicited much higher Ca+current amplitude than WT.Conclusion: We identified a novel GOF mutation p.Q134P ofTRPC6which contributed to late‐onset FSGS. Our study expands the mutational spectrum ofTRPC6associated with FSGS and furtherly supports the hypothesis of calcium dose–response dependency that a moderate increased calcium influx elicited a mild FSGS phenotype.


  • Genotypic and phenotypic analysis in 51 Chinese patients with primary distal renal tubular acidosis

    by Wencong Guo, Qijing Song, Ruixiao Zhang, Qing Xin, Zhiying Liu, Yanhua Lang, Xiangzhong Zhao, Leping Shao

    The aim of this study was to analyze the genetic variants of 51 Chinese patients with distal renal tubular acidosis (dRTA) and explore the correlation between their genotype and phenotype. Eight variants of SLC4A1, 19 variants of ATP6V0A4, and 16 variants of ATP6V1B1 have been identified, and of which 14 were novel ones. Eleven patients with autosomal dominant dRTA, and four patients with autosomal recessive dRTA were caused by genetic defects in SLC4A1; 18 and nine patients with recessive dRTA were resulted by defects in ATP6V0A4 and ATP6V1B1 respectively; no causal gene was identified in seven patients. Mutation frequency of SLC4A1 in Chinese populations was more common than Europeans. The incidence of deafness in ATP6V0A4 and ATP6V1B1 groups was 16.7% and 54.5%, respectively. The frequency of CKD in adults, children and infants was 100%, 51%, and 3%, separately. Our study will further expand the mutation spectrum of primary dRTA and provide valuable references to genetic counseling of Chinese populations.


  • Open Access

    Novel compound heterozygous ATP6V1B1 mutations in a Chinese child patient with primary distal renal tubular acidosis: a case report

    by Xiangzhong Zhao, Jingru Lu, Yanxia Gao, Xiaoling Wang, Yanhua Lang, Leping Shao

    Distal renal tubular acidosis (dRTA) is a heterogeneous disorder characterized by normal anion gap metabolic acidosis. Autosomal recessive dRTA is usually caused by mutations occurring in ATP6V1B1 and ATP6V0A4 genes,encoding subunits B1 and a4 of apical H+-ATPase, respectively. The heterogeneous clinical manifestations of dRTA have been described in different ethnic groups harboring distinct mutations. Most of the reported cases are from Europe and Africa. At present, the prevalence of primary dRTA is still poorly elucidated in Chinese population. A 2-year and six-month-old female patient was hospitalized because of recurrent hypokalemia, hyperchloremic metabolic acidosis and growth retardation. Laboratory investigations presented a normal anion gap hyperchloremic metabolic acidosis, hypokalemia, and inappropriate alkaline urine. Renal ultrasound indicated bilateral nephrocalcinosis. Bilateral sensorineural hearing loss (SNHL) was confirmed with moderately severe (45 dB) on the left ear and severe (80 dB) on the right ear, which was accompanied with enlarged vestibular aqueduct (EVA) on both sides. According to these findings, a diagnosis of dRTA was made. To identify the pathogenic gene mutation, all coding regions of ATP6V1B1 and ATP6V0A4 gene, including intron-exon boundaries, were analyzed using PCR followed by direct sequence analysis. The splicing variants were verified in peripheral blood leucocytes of the patient by RT-PCR. As a result, two novel heterozygous mutations in ATP6V1B1 were identified in the child. One mutation was a successive 2-nucleotide deletion in exon 2(c.133-134delTG), which caused a marked nonsense mediated mRNA decay. The other was a guanine to adenine substitution of the first nucleotide of intron 8(c.785 + 1 G > A), which led to the exclusion of exon 8. After treatment with sodium citrate, potassium citrateand citric acid, metabolic acidosis and hypokalemia were corrected, but her hearing decreased gradually during the 2 years and had to accept the use of bilateral hearing aids. We described two novel dRTA associated mutations in ATP6V1B1 identified in a Chinese child patient accompanying with SNHL and EVA. Our study will help to expand the understanding of this rare disease in Chinese population.


  • Open Access

    A novel mutation in exon 9 of Cullin 3 gene contributes to aberrant splicing in pseudohypoaldosteronism type II

    by Leping Shao, Li Cui, Jingru Lu, Yanhua Lang, Irene Bottillo, Xiangzhong Zhao

    Pseudohypoaldosteronism type II (PHAII) is a rare renal tubular disease that is inherited in an autosomal dominant manner. Mutations in four genes (WNK1, WNK4, CUL3, and KLHL3) have been identified to be responsible for this disease. Cullin 3 (CUL3) and KLHL3 are subunits of Cullin–RING E3 ubiquitin ligase complexes, and the serine–threonine kinases WNK1 and WNK4 are substrates of this ubiquitin ligase. For CUL3, all mutations associated with PHAII exclusively lead to exon 9 skipping. In this study, we identified a Chinese PHAII kindred caused by a novel synonymous mutation (c.1221A > G p.Glu407Glu) in CUL3, and explored its effects on exon 9 abnormal splicing through an in vitro splicing assay and study of the patients’ RNA. We obtained evidence that this synonymous mutation leads to complete exon 9 skipping, and in silico bioinformatics analysis demonstrated that the CUL3 c.1221A > G mutation might decrease the ratio of exonic splicing enhancers and silencers. This is the first report of PHAII in Chinese patients with a novel CUL3 mutation. Our findings add a novel pathogenic splicing variant to the CUL3 mutational spectrum and provide reference for further research on mechanisms of splicing modulation and development of potential therapeutic reagents for PHAII.


  • Open Access

    Two novel AGXT mutations identified in primary hyperoxaluria type-1 and distinct morphological and structural difference in kidney stones

    by Cui Wang, Jingru Lu, Yanhua Lang, Ting Liu, Xiaoling Wang, Xiangzhong Zhao, Leping Shao

    Primary hyperoxaluria type 1 (PH1) is a rare genetic disease characterized by excessive oxalate accumulation in plasma and urine, resulting in various phenotypes because of allelic and clinical heterogeneity. This study aimed to detect disease-associated genetic mutations in three PH1 patients in a Chinese family. All AGXT exons and 3 common polymorphisms which might synergistically interact with mutations, including P11L, I340 M and IVSI+74 bp were analyzed by direct sequencing in all family members. It demonstrated that in each of three patients, a previously reported nonsense mutation p.R333* was in cis with a novel missense mutation p.M49L in the minor allele characterized by the polymorphism of 74-bp duplication in intron 1, while the other novel missense mutation p.N72I was in trans with both p.R333* and P.M49L in the major allele. Kidney stones from two sibling patients were also observed though stereomicroscopic examination and scanning electron microscopy. Distinct morphological and inner-structure differences in calculi were noticed, suggesting clinical heterozygosity of PH1 to a certain extent. In brief, two novel missense mutations were identified probably in association with PH1, a finding which should provide an accurate tool for prenatal diagnosis, genetic counseling and screening for potential presymptomatic individuals.


  • Open Access

    Induction of Apoptosis, G0/G1 Phase Arrest and Microtubule Disassembly in K562 Leukemia Cells by Mere15, a Novel Polypeptide from Meretrix meretrix Linnaeus

    by Ming Liu, Xiangzhong Zhao, Jin Zhao, Lin Xiao, Haizhou Liu, Cuicui Wang, Linyou Cheng, Ning Wu, Xiukun Lin

    Mere15 is a novel polypeptide from Meretrix meretrix Linnaeus with cytotoxicity in solid cancer cells. In this study, we investigated its activity on human K562 chronic myelogenous leukemia cells. Mere15 inhibited the growth of K562 cells with IC50 values of 38.2 μg/mL. Mere15 also caused concentration dependent induction of apoptosis, with overproduction of reactive oxygen species and loss of mitochondrial membrane potential. Moreover, Mere15 arrested cell cycle progression at G0/G1 phase of K562 cells in a concentration dependent manner. In addition, Mere15 caused the disassembly of the microtubule cytoskeleton in K562 cells and inhibited the polymerization of tubulin in a cell free system via interaction with tubulin. We concluded that Mere15 was cytotoxic to K562 leukemia cells and the cytotoxicity was related to the apoptosis induction, cell cycle arrest and microtubule disassembly. These results implied that Merer15 was a broad spectrum anticancer polypeptide, not only cytotoxic to various solid cancer cells but also to the chronic myelogenous leukemia cells. Mere15 may have therapeutic potential for the treatment of leukemia.